Drug · CHEMBL635
Comparisons in its trials379
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 379
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events | 269 of 701 | 312 of 702 | 1,403 | NCT01287741 | Trial comparisons |
| Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: deaths from any cause | 111 of 692 | 104 of 698 | 1,390 | NCT01332968 | Trial comparisons |
| Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events | 309 of 692 | 361 of 698 | 1,390 | NCT01332968 | Trial comparisons |
Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): Number of Participants Who Has Experienced at Least One Toxicity (Defined as a Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment) | 167 of 657 | 287 of 654 | 1,311 | NCT01949337 | Trial comparisons |
| Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): deaths from any cause | 372 of 657 | 339 of 654 | 1,311 | NCT01949337 | Trial comparisons |
| Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): serious adverse events | 232 of 657 | 269 of 654 | 1,311 | NCT01949337 | Trial comparisons |
| Aflibercept vs Placebo: serious adverse events | 331 of 611 | 184 of 598 | 1,209 | NCT00519285 | Trial comparisons |
| Abiraterone Acetate vs Placebo: Number of Patients Achieving a Prostate-Specific Antigen Decline >=50% | 232 of 797 | 22 of 398 | 1,195 | NCT00638690 | Trial comparisons |
| Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2: serious adverse events | 177 of 580 | 257 of 595 | 1,175 | NCT01308580 | Trial comparisons |
| Placebo + Prednisone vs Orteronel + Prednisone: Number of Participants With Best Pain Response | 72 of 365 | 166 of 734 | 1,099 | NCT01193257 | Trial comparisons |
| Pbo + Abi vs Ipat + Abi: deaths from any cause | 358 of 546 | 331 of 551 | 1,097 | NCT03072238 | Trial comparisons |
| Pbo + Abi vs Ipat + Abi: serious adverse events | 158 of 546 | 252 of 551 | 1,097 | NCT03072238 | Trial comparisons |
| Placebo + Prednisone vs Orteronel + Prednisone: Number of Participants With Abnormal Physical Examination Findings | 0 of 363 | 1 of 732 | 1,095 | NCT01193257 | Trial comparisons |
| Placebo + Prednisone vs Orteronel + Prednisone: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings | 1 of 363 | 3 of 732 | 1,095 | NCT01193257 | Trial comparisons |
| Placebo + Prednisone vs Orteronel + Prednisone: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) | 345 of 363 | 719 of 732 | 1,095 | NCT01193257 | Trial comparisons |
| Placebo + Prednisone vs Orteronel + Prednisone: serious adverse events | 148 of 363 | 384 of 732 | 1,095 | NCT01193257 | Trial comparisons |
| Docetaxel/Prednisone/Lenalidomide (DPL) vs Docetaxel/ Prednisone/and Placebo (DP): serious adverse events | 283 of 525 | 176 of 521 | 1,046 | NCT00988208 | Trial comparisons |
| Docetaxel + Placebo vs Docetaxel + Bevacizumab: serious adverse events | 237 of 505 | 178 of 504 | 1,009 | NCT00110214 | Trial comparisons |
| Arm II: Atrasentan vs Arm I: Placebo: Compare Prostate Specific Antigen (PSA) Response Rates Between the Experimental Arm and the Standard Arm. | 249 of 498 | 243 of 496 | 994 | NCT00134056 | Trial comparisons |
| Placebo+ Abiraterone Acetate - Prednisolone vs Apalutamide + Abiraterone Acetate - Prednisolone: deaths from any cause | 350 of 489 | 338 of 490 | 979 | NCT02257736 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL635/comparisons